<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04765800</url>
  </required_header>
  <id_info>
    <org_study_id>DiW-KIP</org_study_id>
    <nct_id>NCT04765800</nct_id>
  </id_info>
  <brief_title>Differential Efficacy of Guided Imagery Psychotherapy</brief_title>
  <acronym>DE-GIP</acronym>
  <official_title>Differential Efficacy of Guided Imagery Psychotherapy [Differentielle Wirksamkeit Katathym Imaginativer Psychotherapie (DiW-KIP-Studie)]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kassel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsche Gesellschaft für Katathym Imaginative Psychotherapie (DGKIP)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kassel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate, if Guided Imagery Psychotherapy (GIP) is at&#xD;
      least as effective as the established psychodynamic therapy (according to the unified&#xD;
      protocol) for the treatment of emotional disorders. It shall then be investigated whether GIP&#xD;
      is more effective for patients meeting the GIP differential indication criteria than for&#xD;
      patients who do not meet these criteria. Furthermore, it will be tested whether GIP is more&#xD;
      effective than the unified psychodynamic protocol for patients who meet the GIP differential&#xD;
      indication criteria.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2021</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in severity of depressive symptoms as measured by the PHQ-9</measure>
    <time_frame>6 months after starting treatment</time_frame>
    <description>Patient Health Questionnaire 9 Item [range: 0-27]; improvement is indicated by lower scores</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in severity of depressive symptoms as measured by the PHQ-9</measure>
    <time_frame>48 months after starting treatment</time_frame>
    <description>Patient Health Questionnaire 9 Item [Range: 0-27]; improvement is indicated by lower scores</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in severity of anxiety symptoms as measured by the Cross-D anxiety scale</measure>
    <time_frame>6 months after starting treatment</time_frame>
    <description>Cross-cutting Dimensional Scale [range: 0-32]; improvement is indicated by lower scores</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in severity of anxiety symptoms as measured by the Cross-D anxiety scale</measure>
    <time_frame>48 months after starting treatment</time_frame>
    <description>Cross-cutting Dimensional Scale [range: 0-32]; improvement is indicated by lower scores</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in severity of interpersonal problems as measured by the IIP-32</measure>
    <time_frame>48 months after starting treatment</time_frame>
    <description>Inventory of Interpersonal Problems 32 [range: 0-4]; improvement is indicated by lower scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life as measured by the WHOQOL-BREF</measure>
    <time_frame>48 months after starting treatment</time_frame>
    <description>WHO Quality of Life-BREF [range: 0-100]; improvement is indicated by higher scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in structural integration as measured by the OPD-SQS</measure>
    <time_frame>48 months after starting treatment</time_frame>
    <description>OPD Structure Quesionnaire Brief [range: 0-4]; improvement is indicated by lower scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in level of personality functioning as measured by the LPFS-BF</measure>
    <time_frame>48 months after starting treatment</time_frame>
    <description>Level of Personality Functioning Scale-Brief Form [range: 1-4]; improvement is indicated by lower scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in self-efficacy as measured by the module &quot;self-efficacy&quot; from the HEALTH-49</measure>
    <time_frame>48 months after starting treatment</time_frame>
    <description>Hamburg Modules for the Assessment of Psychosocial Health [range: 0-4]; improvement is indicated by lower scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in difficulties in emotion regulation as measured by the DERS-SF</measure>
    <time_frame>48 months after starting treatment</time_frame>
    <description>Difficulties in Emotion Regulation Scale Short Form [range: 1-5]; improvement is indicated by lower scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in alexithymia as measured by the TAS-26</measure>
    <time_frame>48 months after starting treatment</time_frame>
    <description>Toronto Alexithymia Scale (26 items) [range: 26-130]; improvement is indicated by lower scores</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Emotional Disorders</condition>
  <arm_group>
    <arm_group_label>Unified Psychodynamic Protocol for Emotional Disorders (UPP-EMO)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>focus on core psychodynamic treatment principles (Leichsenring &amp; Steinert, 2018); no use of imagery-based interventions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Guided Imagery Psychotherapy for Emotional Disorders (GIP-EMO)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>regular sessions with and focus on work with guided affectice imagery</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>weekly sessions of face to face outpatient psychotherapy</intervention_name>
    <description>according the German Richtlinie des Gemeinsamen Bundesausschusses über die Durchführung der Psychotherapie</description>
    <arm_group_label>Guided Imagery Psychotherapy for Emotional Disorders (GIP-EMO)</arm_group_label>
    <arm_group_label>Unified Psychodynamic Protocol for Emotional Disorders (UPP-EMO)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Depressive Disorder, anxiety disorder or somatic symptom disorder (with comorbid&#xD;
             depressive or anxiety disorder) according to DSM-IV (SCID) as main diagnosis&#xD;
&#xD;
          -  informed consent to participate voluntarily in the study&#xD;
&#xD;
          -  sufficient German language skills&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  acute suicidality&#xD;
&#xD;
          -  diagnosis of schizophrenia, schizophreniform, schizoaffective disorders, and/or&#xD;
             psychosis NOS&#xD;
&#xD;
          -  bipolar disorder&#xD;
&#xD;
          -  depressive disorder with mood-incongruent psychotic features&#xD;
&#xD;
          -  paranoid/ schizotypal/ borderline/ or antisocial personality disorder&#xD;
&#xD;
          -  severe neurological disorder&#xD;
&#xD;
          -  PTSD with intrusive re-experiencing&#xD;
&#xD;
          -  clinically relevant substance dependence&#xD;
&#xD;
          -  psychopharmacological treatment other than antidepressants&#xD;
&#xD;
          -  other simultaneous psychological treatments&#xD;
&#xD;
          -  organic cause of depression/anxiety or drug-induced depression/anxiety&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Sell, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kassel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cord Benecke, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kassel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Sell, Dr.</last_name>
    <phone>+49 561 804</phone>
    <phone_ext>2896</phone_ext>
    <email>csell@uni-kassel.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cord Benecke, Prof.</last_name>
    <phone>+49 561 804</phone>
    <phone_ext>3630</phone_ext>
    <email>benecke@uni-kassel.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Kassel</name>
      <address>
        <city>Kassel</city>
        <state>Hessen</state>
        <zip>34127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jule Bauckhage, M.Sc.</last_name>
      <phone>+49 561 804</phone>
      <phone_ext>2871</phone_ext>
      <email>diw-kip@uni-kassel.de</email>
    </contact>
    <contact_backup>
      <last_name>Christian Sell, Dr.</last_name>
      <phone>+49 561 804</phone>
      <phone_ext>2896</phone_ext>
      <email>csell@uni-kassel.de</email>
    </contact_backup>
    <investigator>
      <last_name>Jule Bauckhage, M.Sc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Sell, C., Möller, H. &amp; Taubner, S. (2018). Effectiveness of Integrative Imagination- and Trance-Based Psychodynamic Therapies: Guided Imagery Psychotherapy &amp; Hypnopsychotherapy. Jour-nal of Psychotherapy Integration, 28(1), 90-113. doi: 10.1037/int0000073</citation>
  </reference>
  <reference>
    <citation>Sell, C., Möller, H. &amp; Taubner, S. (2017). Katathym Imaginative Psychotherapie und Hypnosepsy-chotherapie: Symptomreduktion und Prädiktoren des Behandlungserfolgs. Psychotherapeut, 62, 547-559. doi: 10.1007/s00278-017-0230-8</citation>
  </reference>
  <reference>
    <citation>Sell, C., Schöpfer-Mader, E., Brömmel, B. &amp; Möller, H. (2017). Therapeutisches Vorgehen und In-terventionen in Katathym Imaginativer Psychotherapie, Hypnosepsychotherapie und Autogener Psychotherapie: Entwicklung und Validierung der Therapeutenversion der 'Prozessskala für ima-ginations- und trancebasierte tiefenpsychologische Methoden' (PIT). Psychotherapie Forum, 22(4), 113-126. doi: 10.1007/s00729-017-0102-2</citation>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 15, 2021</study_first_submitted>
  <study_first_submitted_qc>February 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>February 19, 2021</last_update_submitted>
  <last_update_submitted_qc>February 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Kassel</investigator_affiliation>
    <investigator_full_name>Christian Sell</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>depression</keyword>
  <keyword>anxiety</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all IPD that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

